Geron Stock (NASDAQ:GERN)
Previous Close
$1.28
52W Range
$1.17 - $4.89
50D Avg
$1.42
200D Avg
$2.48
Market Cap
$802.52M
Avg Vol (3M)
$10.48M
Beta
0.65
Div Yield
-
GERN Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
Annual
| Product/Service | Dec 24 |
|---|---|
| Chargeback And Distributor Service Fees | $-11.77M |
| Government Rebates | $-926.00K |
| Product | $76.50M |
| Revenues Before Adjustments | $89.42M |
| Sales Returns And Allowance | $-225.00K |
| Total Gross To Net Adjustments | $-12.92M |
Latest
Fiscal year ends in Dec 24 | Currency in USD